{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-23-000008","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.388953+00:00","generated_at":"2026-06-17T20:44:45.187038+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Novavax President of R&D Gregory Glenn retiring March 31, signs consulting agreement through Dec 2024","bullets":["Dr. Gregory Glenn steps down as President, R&D effective March 31, 2023.","Consulting agreement provides $25k/month for first 12 months, then $12.5k/month through Dec 31, 2024.","Equity awards continue to vest during consulting period; non-competition covenants begin post-retirement.","He will serve as Strategic Research & Development Advisor after retirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-23-000008","json":"https://secwatch.observer/filing/0001000694-23-000008.json","markdown":"https://secwatch.observer/filing/0001000694-23-000008.md","text":"https://secwatch.observer/filing/0001000694-23-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/0001000694-23-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/nvax-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T20:44:45.187038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ad95faa044","claim":"Gregory M. Glenn retired as President, Research and Development at NOVAVAX INC.","evidence_excerpt":"Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069423000008/0001000694-23-000008-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"President, Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}